

## Grifols and the Public Investment Fund of Saudi Arabia taking steps to boost plasma medicines self-supply in the region

- *Grifols and the Public Investment Fund of Saudi Arabia (PIF) have executed a non-binding term sheet to build a network of plasma collection centers and other facilities for the production of plasma medicines, including a plasma fractionation plant and a purification plant, in Saudi Arabia.*
- *Following definitive agreements being signed, the project would be executed through a joint venture which will be owned jointly by Grifols and PIF.*
- *This partnership creates a unique opportunity for a collaboration that will allow Grifols to reinforce its presence in the region, as well as strengthen the Saudi Arabian Healthcare System.*

**Barcelona (Spain), February 18, 2020** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global company with more than 100 years of experience contributing to improving people’s health and well-being and a leader in plasma medicines, transfusion diagnosis and pharmaceutical specialists for hospital use has executed a non-binding term sheet with PIF in order to boost the self-supply of plasma medicines in the region.

Through this planned joint venture, the parties would develop collection centers, production facilities, including a fractionation facility and a purification facility.

Víctor Grífols Deu, Co-CEO of Grifols, commented: “We are very satisfied to form part of the collaboration which will contribute to the development of the Saudi Arabian health system and will allow more people to have access to our treatments”.

The leadership in the production of plasma medicines, the experience and reputation in the construction and management of plasma centers and production facilities, and the solid presence and knowledge of the area, have been highly valued factors for the Public Investment Fund of Saudi Arabia to choose Grifols as a strategic partner.

The agreed term sheet is non-binding and Grifols and PIF envisage working towards executing definitive agreements thereafter.

# GRIFOLS

*An unprecedented partnership to contribute to the improvement of the country's health*

The financing needs of the project will be determined by the parties depending on the specific needs of each phase of the project.

Part of the recognized value that Grifols would contribute to the joint venture includes its knowledge and expertise in the industry, as well as the intellectual property it holds. Grifols would provide engineering services and support for the quality assurance of infrastructure and processes according to the strictest quality and safety standards.

Furthermore, until the infrastructures are operational, Grifols will guarantee the supply of plasma-derived products to Saudi Arabia, through supply, manufacturing and distribution agreements to be entered into.

For this transaction, Osborne Clarke España, S.L.P. is acting as legal counsel to Grifols.

## Investor contact:

### Investor Relations

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Phone number: +34 93 571 02 21

## Media contacts:

Raquel Lumbreras <a href="mailto:Raquel_lumbreras@duomocomunicacion.com">Raquel_lumbreras@duomocomunicacion.com</a> Borja Gómez <a href="mailto:Borja_gomez@duomocomunicacion.com">Borja_gomez@duomocomunicacion.com</a> Duomo Comunicación – <b>Grifols PR office</b> Phone number. +34 91 311 92 89 - 91 311 92 90	Brad Pick <b>Grifols Corporate Communications</b> <a href="mailto:Brad.pick@grifols.com">Brad.pick@grifols.com</a>
---	--

# GRIFOLS

## About the Public Investment Fund

For information on PIF please visit [www.pif.gov.sa](http://www.pif.gov.sa)

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.